---
title: "Executive Summary: Substance Use Disorder"
date: 2026-06-25
author: "Syam Adusumilli"
summary: "Executive summary of Substance Use Disorder"
tags: ["rural-health", "rhtp", "health-equity", "series-9", "summary"]
showtoc: false
ShowReadingTime: true
ShowBreadCrumbs: true
params:
  is_summary: true
  full_article_url: "../substance-use-disorder/"
  article_id: "RHTP-9M-Summary"
  collection: "rural-health"
weight: 999
cover:
  image: "cover.webp"
  alt: "Cover image"
  relative: true
build:
  list: never
---


The substance use disorder treatment gap in rural America represents not population characteristics but systematic healthcare exclusion. Approximately 3.2 million rural adults meet criteria for SUD, with 89% receiving no treatment despite evidence that medication-assisted treatment reduces opioid use by 50-80% at effectiveness rates matching insulin for diabetes. The challenge confronting the Rural Health Transformation Program's $50 billion investment is whether healthcare funding can overcome structural discrimination that created treatment deserts no community would tolerate for any other medical condition. **Fifty-eight percent of rural counties have no MAT prescriber, median distance to opioid treatment programs reaches 74 miles, and same-day treatment availability exists in only 12% of rural facilities compared to 35% urban.** These gaps do not reflect resource scarcity but policy choices about what conditions merit treatment, where providers will practice, and which patient populations healthcare systems will serve.

The dominant framing treats SUD as medical condition requiring medical intervention, correctly identifying that treatment produces better outcomes than incarceration or abstinence-only approaches. Yet this medical framing obscures why medical treatment for this medical condition simply does not exist in most rural areas. Communities mobilize against addiction treatment facilities using zoning mechanisms unavailable for other healthcare services. Providers face reimbursement structures that discourage addiction medicine specialization. Patients encounter employment, housing, and child custody discrimination that penalizes treatment-seeking. The infrastructure absence is constructed through deliberate choices, not natural distribution. When Vermont developed its hub-and-spoke MAT network, treatment became accessible and outcomes improved. When neighboring regions received no equivalent investment, treatment deserts persisted and overdose deaths increased. **The difference was not population willingness or disease characteristics but system capacity.**

Rural overdose death rates now exceed urban rates at 35.2 per 100,000 compared to 29.8 per 100,000, reversing historical patterns and widening annually. The opioid epidemic that reached rural America through prescription painkillers transitioned to heroin and synthetic fentanyl, each phase increasing lethality while decreasing harm reduction effectiveness. Methamphetamine resurged across agricultural regions with no FDA-approved medication treatment. Alcohol use disorder, affecting 11% of rural adults who drink, receives minimal policy attention despite causing more total health harm than any single illegal substance. Polysubstance use increasingly characterizes rural SUD presentations, complicating treatment protocols designed for single substances. RHTP applications universally acknowledge crisis severity and promise treatment expansion, yet the workforce constraints and community attitudes that created deserts persist regardless of federal investment.

The 2016 Comprehensive Addiction and Recovery Act and 2023 elimination of DATA 2000 waiver requirements removed regulatory barriers to buprenorphine prescribing. Any DEA-registered practitioner can now prescribe MAT without special certification. Rural primary care providers remain reluctant despite regulatory flexibility, citing concerns about practice disruption, patient complexity, inadequate behavioral health support, and community stigma. Some fear that treating addiction will transform patient panels in unmanageable ways. Others face informal pressure from communities that do not want addiction treatment locally. **The barrier was never primarily regulatory but provider willingness in contexts of inadequate support and active resistance.** Policy removed obstacles that were not the binding constraint.

Treatment infrastructure collapse extends beyond prescriber scarcity to encompass the full care continuum. Rural patients requiring residential treatment face 300-mile journeys to available beds with wait times exceeding one month. Treatment motivation operates within time-limited windows that delay and distance predictably close. Outpatient counseling, when available, often lacks MAT integration despite overwhelming evidence that combined approaches produce superior outcomes to either intervention alone. Peer recovery support that sustains long-term recovery after initial treatment barely exists in rural communities. Alcoholics Anonymous and Narcotics Anonymous meetings require driving distances that strain recovery maintenance. **The absence of recovery infrastructure converts treatment successes into eventual relapses**, treating acute episodes without addressing chronic condition management that evidence identifies as essential.

RHTP provides meaningful SUD investment in states with existing infrastructure to build upon. Vermont's hub-and-spoke model, the national exemplar for rural opioid use disorder treatment, receives enhancement funding to extend already-functioning systems. Kentucky's EmPATH expansion builds on demonstrated success connecting crisis response to treatment pathways. These investments will improve outcomes for populations accessing enhanced services. RHTP fails populations in states starting from infrastructure absence. Texas receives minimal per-capita funding and proposes no treatment system reaching rural communities. Mississippi mentions SUD without specific infrastructure plans. **States where crisis severity is greatest often possess least capacity to respond.** The universal approach also treats SUD primarily as opioid problem because federal attention and evidence concentrate there. Methamphetamine receives minimal specific intervention. Alcohol receives almost none. Polysubstance use falls between categorical approaches.

Medicaid expansion status determines treatment availability more than any other policy variable. Coverage directly translates into infrastructure development because Medicaid pays for MAT and providers locate where payment exists. Non-expansion states that rejected coverage also rejected treatment system development. Opioid litigation settlements represent potential transformation opportunity as billions flow to states from manufacturer and distributor agreements. Some states require settlement funds support SUD treatment and prevention. Others allow diversion to general funds or non-SUD purposes. **States directing settlement resources to infrastructure may achieve capacity gains that RHTP alone cannot produce**, but coordination remains uncertain.

The intersection with serious mental illness creates particularly severe compound challenges. More than half of individuals with SUD have co-occurring mental health conditions. More than half with serious mental illness have co-occurring SUD. Treatment systems remain largely separate, with mental health programs often not addressing substance use and SUD programs not addressing mental health. Patients with both conditions frequently receive treatment for neither because neither system is equipped for integrated care. Justice involvement creates destructive cycling as incarceration interrupts treatment, often prohibits MAT even for stable patients, and releases individuals without treatment connection into predictable relapse and reincarceration. **Criminal justice systems cycle populations through institutional contact without achieving either punishment's deterrent goals or treatment's recovery goals.**

The evidence demonstrates what works. Medication-assisted treatment for opioid use disorder produces outcomes comparable to standard treatments for other chronic conditions. Hub-and-spoke networks extend treatment access by connecting specialty addiction providers with primary care practices. Peer recovery support improves long-term recovery maintenance. Emergency department-initiated buprenorphine connects crisis presentations to ongoing care. These interventions exist and can be implemented in rural settings. What cannot be implemented within RHTP timelines is cultural transformation enabling treatment infrastructure to develop in communities that actively resist it. Jefferson County, Tennessee and Scott County, Tennessee, both rural Appalachian communities with similar populations and opioid devastation, show divergent outcomes based solely on whether grant funding built treatment networks. **The difference was not population characteristics but system capacity.**

States with existing infrastructure will use RHTP to expand functioning systems through enhanced hub-and-spoke networks, integrated primary care MAT, and expanded peer support. States without infrastructure face harder paths because building treatment networks from nothing requires more than funding. It requires willing providers, accepting communities, and coordinated systems that do not exist in treatment deserts. RHTP can fund what states propose but cannot create conditions making proposals viable in communities starting from zero. Transformation also requires interventions beyond healthcare scope. SUD populations need housing that does not exclude people in recovery, employment accommodating treatment schedules, communities that accept rather than stigmatize, and legal systems that divert rather than incarcerate. **Healthcare-focused investment alone cannot address problems extending across housing, employment, criminal justice, and social attitudes.**

The honest assessment reveals that RHTP will help some rural SUD populations in some states while leaving others in treatment deserts that existed before federal investment and will persist after. This outcome does not represent program failure but policy confronting structural constraints that program design cannot overcome. The question is not whether evidence-based treatment works (it does) or whether rural populations would engage treatment if accessible (they would). The question is whether $50 billion invested during simultaneous $911 billion Medicaid cuts can overcome discrimination, stigma, workforce economics, and community resistance that created systematic exclusion from effective treatment. For states like Vermont with foundation infrastructure, RHTP enables meaningful expansion. For states like Texas or Mississippi with treatment deserts and minimal per-capita allocations, the transformation remains hypothetical. The core tension persists between what healthcare investment can purchase and what social transformation requires beyond purchasable inputs. Treatment works when it exists, but existence requires more than funding can guarantee.